Advertisement

Klinische Wochenschrift

, Volume 65, Issue 1, pp 22–26 | Cite as

HTLV-III antibody prevalence among young delinquent drug abusers in long-term residential treatment at a north-German drug clinic

  • G. Paschelke
  • G. Altvater-Kremer
  • W. D. Meyer
  • H. Kremer
Originalien
  • 11 Downloads

Summary

To date, long-term intravenous drug users studied at regional European centers of illicit drug use have had a high number of LAV/HTLV-III infections. Among 200 patients remanded by court or referred from prison to a special clinic in northern Germany for young delinquent drug abusers, 26 (17%) of 157 IV drug abusers were HTLV-III seropositive. With 40% seropositive, female patients showed a significantly higher prevalence of HTLV-III infection than males. The results of longitudinal serological, immunological, and clinical observations over periods of 12 months and 2–3 years indicate that under conditions of continuous medical surveillance, sound preventive counseling, and steady therapeutic care during long-term coeducative residential treatment of drug abusers, neither detectable HTLV-III transmission nor definite progression of HTLV-III induced impairment of immune regulatory functions must ensue.

Key words

Intravenous drug abusers Acquired immunodeficiency syndrome Immunocompetence Longitudinal study LAV/HTLV-III 

Abbreviations

AIDS

acquired immune deficiency syndrome

CDC

Centers for Disease Control

HTLV-III

human T-lymphotropic virus type III

IV

intravenous

LAV

lymphadenopathy-associated virus

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Angarano G, Pastore G, Monno L, Santantonio T, Zuchena N, Schiraldi O (1985) Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet II:1302Google Scholar
  2. 2.
    Curran JW, Meade Morgan W, Hardy AM, Jaffe HW, Darrow WW, Dowdle WR (1985) The epidemiology of AIDS — current status and future prospects. Science 229:1552Google Scholar
  3. 3.
    Ferroni P, Geroldi D, Galli C, Zanetti AR, Carguel A (1985) HTLV-III antibody among Italian drug addicts. Lancet II:52–53Google Scholar
  4. 4.
    Fuchs D, Blecha HG, Deinhardt F, Dierich MP, Goebel FD, Hengster P, Hinterhuber H, Schoenitzer D, Traill K, Wachter H (1985) High frequency of HTLV-III antibodies among heterosexual intravenous drug abusers in the Austrian Tyrol. Lancet I:1506Google Scholar
  5. 5.
    Ginzburg, HM (1985) Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep 99:206–212Google Scholar
  6. 6.
    Hunsmann G, Schneider J, Bayer H, Kurth R, Werner A, Brede HD, Erfle V, Mellert W. Brodt HR, Bergmann L, Helm I, Scherrer I, Krenz W, Berthold H, Wernet P, Schneider EM, Schimpf K, Egli U, Bienzle U, Schmitz H, Kern P, Krüger G, Rasokat H, Lechler E. Seifried E, Hellstern P, Schneider W, Holzer E, Goebel FD, Hehlmann R (1985) Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. Klin Wochenschr 63:233–235PubMedGoogle Scholar
  7. 7.
    Joller-Jemelka HI, Wilhelm U, Steffen R, Grob PJ (1985) Virale Hepatitis und AIDS-assoziierte HTLV-III/LAV-Virusinfektionen bei Drogenabhängigen. Schweiz Med Wochenschr 115 (33):1114–1119PubMedGoogle Scholar
  8. 8.
    Mortimer PP, Vandervelde EM, Jesson WJ, Pereira MS, Burkhardt F (1985) HTLV-III antibody in Swiss and English intravenous drug abusers. Lancet II:449–550Google Scholar
  9. 9.
    Peutherer JF, Edmond E, Simmonds P, Dickson PD, Bath GE (1985) HTLV-III antibody in Edinburgh drug addicts. Lancet II:1129–1130Google Scholar
  10. 10.
    Rodrigo JM, Serra MA, Aguilar E, Del Olmo JA, Gimeno V, Aparisi L (1985) HTLV-III antibodies in drug addicts Spain. Lancet II:156–157Google Scholar
  11. 11.
    Schüpbach J, Vogt M, Bhushan R, Lüthy R, Haller O, Joller H, Ferber T, Büchner S, Schuppli R, Schädelin J, Hirschel B, Cruchand A, Stroun J, Frei P, Glauser MP (1985) Prävalenz von Antikörpern gegen HTLV-III in verschiedenen Regionen der Schweiz. Schweiz Med Wochenschr 115 (30):1048–1054PubMedGoogle Scholar
  12. 12.
    Spira TJ, Des Jarlais DC, Marmor M, Yancovitz S, Friedman S, Garber J, Cohen H, Cabradilla, Kalyanaraman VC (1984) Prevalence of antibody to lymphadenopathy-associated virus among drug-detoxification patients in New York. N Engl J Med 7:467–468Google Scholar
  13. 13.
    Tirelli U, Vaccher E, Carbone A, DePaoli P, Santini GF, Monfardini S (1985) HTLV-III antibody in prostitutes. Lancet II:1424Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • G. Paschelke
    • 1
  • G. Altvater-Kremer
    • 1
  • W. D. Meyer
    • 1
  • H. Kremer
    • 1
  1. 1.Niedersächsisches Landeskrankenhaus BrauelGermany

Personalised recommendations